A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of Pembrolizumab plus Chemotherapy with or without Binimetinib in Participants with Metastatic Colorectal Cancer KEYNOTE-651
Research payments
$3,270,756
Through program year 2024, $3,270,756 in research payments was reported against A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of Pembrolizumab plus Chemotherapy with or without Binimetinib in Participants with Metastatic Colorectal Cancer KEYNOTE-651, across 167 payments, paid by Merck Sharp & Dohme Corporation.
- Paid by
- Merck Sharp & Dohme Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $39,033 | 14 |
| 2023 | Research | $138,151 | 15 |
| 2022 | Research | $622,247 | 33 |
| 2021 | Research | $1,783,385 | 23 |
| 2020 | Research | $687,939 | 82 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Richard Kim Cleveland, OH Named on 61 payments
- Lucas Wong Temple, TX Named on 29 payments
- Blase Polite Chicago, IL Named on 18 payments
- Jeremy Kortmansky Hamden, CT Named on 6 payments
- Christopher Lieu Aurora, CO Named on 5 payments
- Jorge Chaves Tacoma, WA Named on 5 payments
- Marwan Fakih Duarte, CA Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.